Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 154

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.

PT373 – Integrative Psychiatry & The Safety of At-Home Ketamine

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of...

PT372 – The Heroic Hearts Project: Veterans and The Impact of...

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Healthline – Mental Health Breakthrough: The Therapeutic Benefits of Psychedelics

PsychCentral – All About Psychedelic Therapy

PsychCentral – Microdosing Psychedelics Linked to Lower Anxiety, Depression, Stress

Load more

EDITOR PICKS

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©